Aims: Lipoprotein(a) [Lp(a)] levels are known to be mainly genetically determined. However, only scarce data are available on the intra-individual variability of Lp(a) levels across time.
Methods: We included adult patients (≥18 years old) who had baseline and follow-up Lp(a) measurements (between 1997 and 2024) with a minimum of one year apart. Patients were categorized into three groups as follows: normal (<30 mg/dL), borderline (30 to 50 mg/dL) and high Lp(a) (≥50 mg/dL). Multivariable logistic regression was conducted to assess the predictors of the intra-individual changes in Lp(a) ≥10 mg/dL.
Results: A total of 11,669 individuals (median age: 54 years, 60% males) were included in our analysis, with median time between measurements of 4.5 years (IQR: 2.2, 10.6). The median Lp(a) was 16 mg/dL (IQR: 7, 52) at baseline, compared with 15 mg/dL (IQR: 7, 52) at follow-up. At follow-up, 96.4% of individuals with normal Lp(a) and 89.9% with high Lp(a) remained in their categories, while 51.2% with borderline Lp(a) changed their category. Of the included population, 24.9% had an intra-individual Lp(a) change ≥10 mg/dL. Female sex (p <0.001), history of ASCVD (p=0.003), statin therapy (p=0.003) and elevated low-density lipoprotein cholesterol (LDL-C) levels ≥100 mg/dL (p <0.001) were significantly associated with higher odds of intra-individual Lp(a) changes ≥10 mg/dL.
Conclusions: Lipoprotein(a) levels were generally stable over time; however, patients with borderline levels may require more than one Lp(a) measurement, especially if they are females, have a history of ASCVD, have elevated LDL-C levels or are on statins therapy.
Keywords: and risk factors; atherosclerosis; cardiovascular diseases; lipoprotein(a); prevention; variability.
In the current study, we included 11,669 adult patients who had baseline and follow-up lipoprotein(a) [Lp(a)] measurements (between 1997 and 2024) with a minimum of one year apart at any of the three Mayo Clinic locations. In total, 96.4% of individuals with normal Lp(a) (<30 mg/dL) and 89.9% with high Lp(a) (≥50 mg/dL) remained in their Lp(a) categories, while 51.2% with borderline Lp(a) (30 to 50 mg/dL) changed their category at follow-up. Additionally, 24.9% of the included patients had an intra-individual Lp(a) change ≥10 mg/dL. Female sex, history of atherosclerotic cardiovascular diseases (ASCVD), statin therapy and elevated low-density lipoprotein cholesterol (LDL-C) levels ≥100 mg/dL were significantly associated with higher odds of intra-individual Lp(a) changes ≥10 mg/dL on multivariable logistic regression analysis. These findings highlight that patients with borderline Lp(a) levels (30 to 50 mg/dL) may require more than one Lp(a) measurement for a comprehensive ASCVD risk assessment, particularly, if they are females, have a history of ASCVD, are on statins therapy, or have elevated LDL-C levels.
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].